Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors

Blood

Volumn 112, Issue 4, 2008, Pages 1151-1153

  Meeks, Shannon L ^a   Healey, John F ^a   Parker, Ernest T ^a   Barrow, Rachel T ^a   Lollar, Pete ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Emory Children's Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BC ANTIBODY; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; C2 ANTIBODY; EPITOPE; MONOCLONAL ANTIBODY; PHOSPHOLIPID; THROMBIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HEMOPHILIA A; HUMAN; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; ANIMAL; ANTIBODY COMBINING SITE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY;

ANIMALS; BINDING SITES, ANTIBODY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIII; FACTOR XA; HEMOPHILIA A; HUMANS; MICE; THROMBIN;

EID: 51649102381     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-01-132639     Document Type: Article

References (22)

1. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, Kogenate. Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A: safety, efficacy, and the development of inhibitors. N Engl J Med. 1993;328:453-459.
2. Bray GL, Gomperts ED. Courtier S, et al. A multi-center study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood. 1994;83:2428-2435.
3. Kreuz W, Ettingshausen CE, Zyschka A, et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost. 2002; 28:285-290.
4. Lusher JM; Lee GA; Kessler CM, Bedrosian CL the Refacto Phase 3 Study Group. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia. 2003;9:38-49.
5. Prescott R, Nakai H, Saenko EL, et al. The inhibitory antibody response is more complex in hemo-philia A patients than in most nonhemophiliacs with fVIII autoantibodies. Blood. 1997:89:3663-3671.
6. Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood. 1982;60:1103-1109.
7. Arai M, Scandella D, Hoyer LW. Molecular basis of factor-VIII inhibition by human antibodies: antibodies that bind to the factor-VIII light chain prevent the interaction of factor-VIII with phospholipid. J Clin Invest. 1989;83:1978-1984.
8. Saenko EL Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor binding to von Willebrand factor. J Biol Ghem. 1994:269:11601-11605.
9. Barrow RT, Healey JF, Jacquemin MG, Saint-Remy JM; Lollar P. Antigenicity of putative phospholipid membrane binding residues in factor VIII. Blood. 2001;97:169-174.
10. Andersson LO, Brown JE. Interaction of factor Vlll-von Willebrand factor with phospholipid vesicles. Biochem J 1981;200:161-167.
11. Lajmanovich A, Hudry-Clergeon G; Freyssinet JM, Marguerie G. Human Factor VIII procoagu-lant activity and phospholipid interactions. Bio-chim BiophysActa. 1981;678:132-136.
12. Saenko EL Scandella D. A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor. J Biol Chem. 1995;270:13826-13833.
13. Scandella D, Gilbert GE, Shima M, et al. Some human inhibitor antibodies recognize a common epitope corresponding to G2 domain amino acids 2248-2312 which overlap a phospholipid binding site. Blood. 1995;86:1811-1819.
14. Shima M, Scandella D, Yoshioka A, et al. Afactor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost. 1993;69:240-246.
15. Nogami K, Shima M, Hosokawa K, et al. Role of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem. 1999;274:31000-31007.
16. Saenko EL, Shima M, Gilbert GE, Scandella D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem. 1996;271:27424-27431.
17. Nogami K, Shima M, Hosokawa K, et al. Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg 1689. J Biol Chem. 2000;275:25774-25780.
18. Meeks SL Healey JF, Parker ET, Barrow RT, Lollar P. Anti-human factor VIII C2 domain antibodies in hemophilia A mice recognize afunction-ally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood. 2007;110:4234-4242.
19. Barrow RT Healey JF Gailani D, Scandella D, Lollar P. Reduction of the antigenicity of factor VIII toward complex inhibitory plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood. 2000;95:557-561.
20. Barrow RT, Lollar P. Neutralization of anti-factor VIII inhibitors by recombinant porcine factor VIII. J Thromb Haemost. 2006;4:2223-2229.
21. Davies DR, Padlan EA. Antibody-antigen complexes. Ann Rev Biochem. 1990;59:439-473.
22. Spiegel PC Jr, Jacquemin M, Saint-Remy JM, Stoddard BL, Pratt KP. Structure of the factor VI11 C2 domain-immunoglobulin G4κ Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood. 2001;98:13-19.